Zobrazeno 1 - 10
of 551
pro vyhledávání: '"G, Vreugdenhil"'
Autor:
J. C. Janssen, B. van Dijk, K. de Joode, M. J. B. Aarts, F. W. P. J. van den Berkmortel, C. U. Blank, M. J. Boers-Sonderen, A. J. M. van den Eertwegh, J. W. B. de Groot, M. Jalving, M. J. A. de Jonge, A. Joosse, E. Kapiteijn, A. M. Kamphuis-Huismans, K. A. T. Naipal, D. Piersma, B. Rikhof, H. M. Westgeest, G. Vreugdenhil, E. Oomen-de Hoop, E. E. A. P. Mulder, Astrid A. M. van der Veldt
Publikováno v:
BMC Cancer, Vol 24, Iss 1, Pp 1-7 (2024)
Abstract Background Patients with irresectable stage III or metastatic melanoma presenting with poor prognostic factors are usually treated with a combination of immune checkpoint inhibitors (ICIs), consisting of ipilimumab and nivolumab. This combin
Externí odkaz:
https://doaj.org/article/ca4c9e5c51fc40759d196932967e286e
Autor:
E. E. A. P. Mulder, K. de Joode, S. Litière, A. J. ten Tije, K. P. M. Suijkerbuijk, M. J. Boers-Sonderen, G. A. P. Hospers, J. W. B. de Groot, A. J. M. van den Eertwegh, M. J. B. Aarts, D. Piersma, R. S. van Rijn, E. Kapiteijn, G. Vreugdenhil, F. W. P. J. van den Berkmortel, E. Oomen-de Hoop, M. G. Franken, B. Ryll, P. Rutkowski, S. Sleijfer, J. B. A. G. Haanen, A. A. M. van der Veldt
Publikováno v:
BMC Cancer, Vol 21, Iss 1, Pp 1-9 (2021)
Abstract Background The introduction of programmed cell death protein 1 (PD-1) blockers (i.e. nivolumab and pembrolizumab) has significantly improved the prognosis of patients with advanced melanoma. However, the long treatment duration (i.e. two yea
Externí odkaz:
https://doaj.org/article/1258e8cfb799432884b62bfb054d74e9
Publikováno v:
PLoS ONE, Vol 16, Iss 5, p e0252021 (2021)
BackgroundThe Multicenter Selective Lymphadenectomy Trial (MSLT-1) comparing survival after a sentinel lymph node biopsy (SLNB) versus nodal observation in melanoma patients did not show a significant benefit favoring SLNB. However, in subgroup analy
Externí odkaz:
https://doaj.org/article/9a89dd95f973468aa61112284de5def7
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Autor:
Christian U. Blank, John B. A. G. Haanen, Doranne L. Hilarius, Michel W. J. M. Wouters, Willeke A. M. Blokx, Franchette W P J van den Berkmortel, Ellen Kapiteijn, Rawa K. Ismail, Geke A. P. Hospers, Jesper van Breeschoten, Alfonsus J. M. van den Eertwegh, Rozemarijn S. van Rijn, Jan Willem B. de Groot, Maureen J.B. Aarts, D Piersma, Astrid A M van der Veldt, G. Vreugdenhil, Marion A. M. Stevense-den Boer, Marye Boers-Sonderen, Karijn P M Suijkerbuijk, Olivier J. van Not, Melissa M. De Meza
Publikováno v:
International Journal of Cancer, 150(5), 816-824. Wiley
van Not, O J, van Breeschoten, J, van den Eertwegh, A J M, Hilarius, D L, de Meza, M M, Haanen, J B, Blank, C U, Aarts, M J B, van den Berkmortel, F W P J, de Groot, J W B, Hospers, G A P, Ismail, R K, Kapiteijn, E, Piersma, D, van Rijn, R S, Stevense-den Boer, M A M, van der Veldt, A A M, Vreugdenhil, G, Boers-Sonderen, M J, Blokx, W A M, Suijkerbuijk, K P M & Wouters, M W J M 2022, ' The unfavorable effects of COVID-19 on Dutch advanced melanoma care ', International Journal of Cancer, vol. 150, no. 5, pp. 816-824 . https://doi.org/10.1002/ijc.33833
International Journal of Cancer, 150, 816-824
International Journal of Cancer, 150, 5, pp. 816-824
International Journal of Cancer, 150(5), 816-824. Wiley-Liss Inc.
International Journal of Cancer, 150(5), 816-824. WILEY
International Journal of Cancer
van Not, O J, van Breeschoten, J, van den Eertwegh, A J M, Hilarius, D L, de Meza, M M, Haanen, J B, Blank, C U, Aarts, M J B, van den Berkmortel, F W P J, de Groot, J W B, Hospers, G A P, Ismail, R K, Kapiteijn, E, Piersma, D, van Rijn, R S, Stevense-den Boer, M A M, van der Veldt, A A M, Vreugdenhil, G, Boers-Sonderen, M J, Blokx, W A M, Suijkerbuijk, K P M & Wouters, M W J M 2022, ' The unfavorable effects of COVID-19 on Dutch advanced melanoma care ', International Journal of Cancer, vol. 150, no. 5, pp. 816-824 . https://doi.org/10.1002/ijc.33833
International Journal of Cancer, 150, 816-824
International Journal of Cancer, 150, 5, pp. 816-824
International Journal of Cancer, 150(5), 816-824. Wiley-Liss Inc.
International Journal of Cancer, 150(5), 816-824. WILEY
International Journal of Cancer
The COVID‐19 pandemic had a severe impact on medical care. Our study aims to investigate the impact of COVID‐19 on advanced melanoma care in the Netherlands. We selected patients diagnosed with irresectable stage IIIc and IV melanoma during the f
Autor:
L.S. ter Maat, I.A.J. van Duin, S.G. Elias, T. Leiner, J.J.C. Verhoeff, E.R.A.N. Arntz, M.F. Troenokarso, W.A.M. Blokx, I. Isgum, G.A. de Wit, F.W.P.J. van den Berkmortel, M.J. Boers-Sonderen, M.F. Boomsma, A.J.M. van den Eertwegh, J.W.B. de Groot, D. Piersma, G. Vreugdenhil, H.M Westgeest, E. Kapiteijn, P.J. van Diest, J.P.W. Pluim, P.A. de Jong, K.P.M. Suijkerbuijk, M. Veta
IntroductionPredicting checkpoint inhibitors treatment outcomes in melanoma is a relevant task, due to the unpredictable and potentially fatal toxicity and high costs for society. However, accurate biomarkers for treatment outcomes are lacking. Radio
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::470a9b2befdc5aca62538db94bf82fde
https://doi.org/10.1101/2022.12.19.22283574
https://doi.org/10.1101/2022.12.19.22283574
Autor:
H. Berna Beverloo, Michelle E.M.H. Westerhuis, Mojca Jongen-Lavrencic, Marianne Stenstra, G. Vreugdenhil, Sterre P.E. Willems
Publikováno v:
Journal of Hematology
The widely use of non-invasive prenatal testing (NIPT) may lead to accidental findings and the discovery of malignancy in pregnancy, often in asymptomatic patients. Diagnosis of such subclinical malignancy during pregnancy in the asymptomatic patient